Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.51
- Piotroski Score 2.00
- Grade N/A
- Symbol (MYMD)
- Company MyMD Pharmaceuticals, Inc.
- Price $1.81
- Changes Percentage (-0.55%)
- Change -$0.01
- Day Low $1.78
- Day High $1.84
- Year High $63.90
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$9.27
- Trailing P/E Ratio -0.21
- Forward P/E Ratio -0.21
- P/E Growth -0.21
- Net Income $-3,999,950
